News

“Heart failure is one of the most costly medical conditions in the world, with 37% of US Medicare dollars alone spent on heart conditions each year,” said Michael

Quark Pharmaceuticals has reported that four of its siRNA R&D platform based programs have met clinical development milestones. Patient enrollment was completed in three clinical studies and a

NicOx has received a filing communication from the FDA stating that the New Drug Application (NDA) for Naproxcinod is accepted for filing. NicOx submitted the NDA on September

Dow has published a new Company Databook: The Elements of Success. This inaugural edition provides comprehensive insight into Dow as a specialty chemicals and advanced materials company. Andrew

InterMune has modified the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of care (SOC) Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in HCV

UK-based Reaxa has received research and development grant from the Northwest Regional Development Agency (NWDA). The fund for R&D amounts to £146K (E164K). The grant is expected to

MMR Information Systems (MMR) and Unis-Tonghe Technology (Zhengzhou) (UNIS) will enter into a definitive agreement by the end of this year to form a joint venture. The joint

BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its Imvamune smallpox vaccine with

Albireo has completed the Phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate